Barclays PLC Tcr2 Therapeutics Inc. Transaction History

Barclays PLC

  • $377 Billion
  • Q3 2024

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 13, 2023
SELL
$0.83 - $1.44 $369 - $640
-445 Reduced 1.33%
33,116 $33,000
Q3 2022

Nov 03, 2022
SELL
$1.86 - $3.75 $3,653 - $7,365
-1,964 Reduced 5.53%
33,561 $60,000
Q2 2022

Aug 12, 2022
SELL
$2.11 - $2.94 $10,448 - $14,558
-4,952 Reduced 12.23%
35,525 $103,000
Q1 2022

May 16, 2022
SELL
$2.4 - $4.71 $20,625 - $40,477
-8,594 Reduced 17.51%
40,477 $111,000
Q4 2021

Feb 14, 2022
BUY
$4.58 - $8.34 $73,458 - $133,765
16,039 Added 48.56%
49,071 $229,000
Q3 2021

Nov 09, 2021
SELL
$8.44 - $18.35 $77,673 - $168,875
-9,203 Reduced 21.79%
33,032 $281,000
Q2 2021

Aug 13, 2021
SELL
$16.41 - $24.71 $107,387 - $161,702
-6,544 Reduced 13.42%
42,235 $694,000
Q1 2021

May 13, 2021
BUY
$20.38 - $34.07 $761,070 - $1.27 Million
37,344 Added 326.58%
48,779 $1.08 Million
Q4 2020

Feb 11, 2021
SELL
$19.0 - $32.63 $67,659 - $116,195
-3,561 Reduced 23.75%
11,435 $353,000
Q3 2020

Nov 12, 2020
BUY
$13.1 - $20.69 $78,953 - $124,698
6,027 Added 67.2%
14,996 $304,000
Q2 2020

Aug 12, 2020
BUY
$6.51 - $16.85 $33,044 - $85,530
5,076 Added 130.39%
8,969 $138,000
Q1 2020

May 13, 2020
SELL
$6.01 - $16.01 $48,031 - $127,951
-7,992 Reduced 67.24%
3,893 $30,000
Q4 2019

Feb 10, 2020
BUY
$12.17 - $17.88 $73,020 - $107,280
6,000 Added 101.95%
11,885 $169,000
Q3 2019

Nov 14, 2019
BUY
$10.15 - $19.53 $47,836 - $92,044
4,713 Added 402.13%
5,885 $89,000
Q2 2019

Aug 14, 2019
SELL
$13.64 - $20.97 $15,631 - $24,031
-1,146 Reduced 49.44%
1,172 $16,000
Q1 2019

May 15, 2019
BUY
$15.01 - $22.15 $34,793 - $51,343
2,318 New
2,318 $40,000

About TCR2 THERAPEUTICS INC.

TCRR Quotes by TradingView
  • Ticker TCRR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,606,400
  • Description
  • TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...
More about TCRR
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email